Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth, driven by a 21% growth in the core testing business [5][25] - Full year total revenue reached $517 million, achieving 16% growth, with nearly 170,000 patients provided clinically actionable information [6][28] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [7][28] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, while Afirma grew 12%, contributing to a total testing volume growth of 16% [5][25] - Testing revenue during Q4 was $135.8 million, an increase of 21% year-over-year, with Decipher and Afirma revenue growth of 27% and 16%, respectively [25][26] - Approximately 18,250 Afirma tests were delivered in Q4, representing 12% volume growth, while Decipher tests reached approximately 27,200, marking 15 consecutive quarters of over 20% year-over-year volume growth [9][11] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The market penetration for Decipher is approximately 33%, indicating significant room for growth as two-thirds of patients are still not utilizing the test [12][52] - The bladder cancer segment is currently a small portion of Decipher's total volume, but there is potential for increased use as clinical evidence develops [80] Company Strategy and Development Direction - The company plans to launch two major products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [8][24] - The company aims to sustain double-digit growth through its portfolio of tests in prostate, thyroid, bladder, and breast cancer [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit revenue growth, supported by a strong pipeline and operational efficiencies [7][24] - The company is focused on building clinical evidence and expanding its market presence, particularly in advanced disease settings [15][19] - Management highlighted the importance of investing in growth drivers while maintaining profitability [28][46] Other Important Information - The company completed the transition of Afirma to a more scalable, lower-cost v2 transcriptome platform, improving operational efficiency [7][10] - The company has a strong cash position, ending the quarter with $412.9 million in cash and cash equivalents, providing flexibility for future investments [25][28] Q&A Session Summary Question: Guidance and Assumptions for 2026 - Management reiterated strong conviction in the 2026 guidance, with factors influencing the high and low ends of the range discussed [32][34] Question: Market Expansion for Prosigna - The potential market for Prosigna is significant, with 225,000 patients annually expected to be addressed by the indication [40] Question: Competitive Dynamics in Decipher Market - Management noted no significant changes in competitive dynamics, with Decipher continuing to show strong growth supported by clinical evidence [52][54] Question: Capital Allocation Strategy - The company maintains a deliberate approach to capital allocation, focusing on organic growth and infrastructure development [69][70]

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth, driven by a 21% growth in the core testing business [5][25] - Full year total revenue reached $517 million, achieving 16% growth, with nearly 170,000 patients provided clinically actionable information [6][28] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [7][28] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, with approximately 27,200 tests delivered, marking the 15th consecutive quarter of over 20% year-over-year volume growth [11][12] - Afirma delivered approximately 18,250 tests in Q4, representing a 12% volume growth, with a market share of approximately 38% [9][10] - Total testing volume for the quarter was approximately 48,000 tests, a 16% increase over the same period in 2024 [25] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The bladder cancer market is transitioning towards more biologically informed evaluations, with Decipher Bladder gaining traction [18][80] - The prostate cancer market penetration for Decipher is approximately 33%, indicating significant room for growth [12][52] Company Strategy and Development Direction - The company plans to launch two major products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [8][24] - The company aims to sustain double-digit growth through its portfolio of tests in prostate, thyroid, bladder, and breast cancer [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit growth, supported by a strong financial profile and ongoing investments in growth drivers [28][30] - The company is optimistic about the upcoming product launches and their potential to drive revenue growth [23][30] - Management highlighted the importance of generating clinical evidence to support product adoption and market penetration [16][47] Other Important Information - The company completed the transition of Afirma to a more scalable, lower-cost v2 transcriptome platform, improving operational efficiency [7][10] - The company has a strong cash position, ending the quarter with $412.9 million in cash and cash equivalents [25][28] Q&A Session Summary Question: Has the conviction in the guidance evolved in any way? - Management reiterated strong conviction in the guidance, with expectations for seasonal trends impacting Q1 performance [32][34] Question: What readout is required for the OPTIMA study to expand the intended use population? - Management indicated that the OPTIMA study includes patients with up to nine nodes, and the results will determine future market expansion [40][41] Question: Can you discuss the competitive dynamics for Decipher? - Management noted that Decipher continues to grow despite competition, with strong evidence supporting its market position [52][54]

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth driven by a strong core testing business which grew 21% [4] - Full year total revenue reached $517 million, achieving 16% growth [5] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [6][29] - Cash from operations for Q4 was $52.6 million, ending the quarter with $412.9 million in cash and cash equivalents [26] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, with approximately 27,200 tests delivered, marking the 15th consecutive quarter of over 20% year-over-year volume growth [11] - Afirma delivered approximately 18,250 tests in Q4, representing 12% volume growth [9] - Total testing volume for Q4 was approximately 48,000 tests, a 16% increase over the same period in 2024 [26] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The market penetration for Decipher is approximately 33%, indicating significant room for growth as two-thirds of patients are not yet utilizing the test [53] - The bladder cancer market is transitioning towards more biologically informed evaluations, with Decipher Bladder being integrated into studies to guide treatment decisions [17][85] Company Strategy and Development Direction - The company plans to launch two new products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [7] - The company aims to sustain double-digit growth through its portfolio of tests across prostate, thyroid, bladder, and breast cancer [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit growth, supported by a strong pipeline and ongoing clinical evidence generation [25][32] - The company is prepared to invest in growth drivers while maintaining profitability, with a focus on clinical evidence and product launches [46][49] - Management highlighted the importance of navigating evolving market dynamics and maintaining a strong operational model [24] Other Important Information - The company achieved significant milestones in 2025, including the launch of Decipher for metastatic patients and the transition of Afirma to a more scalable platform [5][6] - The company is on track to test its 1 millionth patient later this year, reflecting the scale and impact of its platform [5] Q&A Session Summary Question: Has your conviction in the guidance evolved in any way? - Management reiterated strong conviction in guidance, noting seasonal trends and potential drivers for high and low ends of the range [34][35] Question: What readout is required for the OPTIMA study to expand the intended use population? - Management indicated that the OPTIMA study includes enrollment criteria that could allow for expansion, pending positive results [40][42] Question: Can you walk through the push and pulls regarding the margin guidance for 2026? - Management explained that the guidance reflects the need for flexibility to invest in new product launches while maintaining profitability [45][49] Question: How is the competitive landscape for Decipher evolving? - Management noted that Decipher continues to grow despite competition, with strong evidence supporting its use in clinical guidelines [53][55] Question: What is the expected volume growth for Afirma and Decipher in 2026? - Management indicated that Afirma is expected to grow in the mid to high single digits, while Decipher is projected to grow approximately 20% [30][90]

Veracyte FY Conference Summary Company Overview - **Company**: Veracyte (NasdaqGM:VCYT) - **Industry**: Medtech and Diagnostics Key Financial Highlights - **Q3 Revenue**: Over $131 million, a growth of 14% year-over-year [4] - **Testing Business Growth**: Grew by 17%, with Decipher achieving over 25% growth for 14 consecutive quarters [4] - **Afirma Growth**: Volume increased by 13%, driven by new accounts and deeper penetration into existing accounts [4] - **Adjusted EBITDA**: Reached 30% for the quarter, exceeding expectations, with a forecast to finish the year over 25% [5] Decipher Product Insights - **Market Penetration**: Estimated at 40%, indicating room for growth [7] - **Durability of Growth**: Anticipated demand increase due to the recent launch of the metastatic indication and ongoing clinical trials [8][10] - **Physician Ordering Dynamics**: Changes in how tests are ordered, with a focus on building trust and integrating test ordering into clinical workflows [11][12] NCCN Guidelines Impact - **Guideline Inclusion**: The inclusion of Decipher in NCCN guidelines has provided a tailwind for growth, although isolating the impact from other factors is challenging [14] Digital Pathology and Competitive Landscape - **Digital Pathology Positioning**: Emphasized as complementary to existing tests, with a focus on avoiding confusion among clinicians [16] - **Discordance with Competitors**: Noted a 30% discordance rate between Decipher and a competing test, highlighting Decipher's validation and reliability [18][19] Future Product Developments - **V2 Transcriptome Transition**: Aiming for full transition by the end of the year, expected to enhance efficiency and reduce test failures [29][30] - **Prosigna LDT Launch**: Planned for mid-2026, with a focus on building a commercial team and engaging key opinion leaders [42][43] Market Strategy and Growth Drivers - **Growth Drivers**: Focus on Afirma, Decipher, Prosigna, MRD, and IBD, with a balanced approach to investment and growth [62] - **Market Penetration Goals**: Targeting 80% penetration in the market, currently at 65% [28] Capital Allocation and M&A Strategy - **Cash Position**: Expected to be close to $400 million with no debt, allowing for strategic investments and potential M&A opportunities [70] - **M&A Focus**: Prioritizing investments in core business areas before considering acquisitions [71] Conclusion - Veracyte is positioned for continued growth with strong financial performance, innovative product offerings, and a strategic focus on market penetration and operational efficiency. The company is actively engaging in expanding its product portfolio while maintaining a disciplined approach to capital allocation and investment in growth drivers.